Venetoclax-based salvage in multiple myeloma with (11;14) translocation after suboptimal response to first-line therapy
INTRODUCTION: Multiple myeloma is one of the most common hematologic malignancies, with approximately 400 patients diagnosed in Hungary annually. Novel therapies emerging in the last decade have made a great impact on most patients' survival, however, those responding poorly to standard first-line therapy and failing to proceed to stem cell transplantation face a dire prognosis. Venetoclax, a selective Bcl-2 inhibitor has been shown very effective in the treatment of relapsed/refractory t(11;14) patients, but there are only a few studies about its safety and efficacy when used as salvage in the second line.
OBJECTIVE: The aim of our study was to analyze the data of t(11;14) patients treated with venetoclax salvage at our clinic and to evaluate its efficacy.
METHOD: Between 2017 and 2021, 13 patients received venetoclax therapy at our clinic after suboptimal response to frontline treatment, whose data we analyzed retrospectively.
RESULTS: Adverse prognostic markers were very prevalent in our group, 4 of our patients had del(17p), 5 had amp(1q21) and 6 had stage 3. Nevertheless, all 13 patients responded well to venetoclax therapy, with 6 reaching very good partial response and 7 complete response. All eligible patients (10) could proceed to transplantation. After median 38 months follow up, neither median progression-free, nor median overall survival was reached, since only 3 patients progressed and 1 died.
CONCLUSION: We have shown that when salvage is needed for t(11;14) patients who respond suboptimally to standard frontline therapy, venetoclax is a remarkably good option. Orv Hetil. 2023; 164(23): 894-899.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:164 |
|---|---|
| Enthalten in: |
Orvosi hetilap - 164(2023), 23 vom: 11. Juni, Seite 894-899 |
| Sprache: |
Ungarisch |
|---|
| Weiterer Titel: |
Venetoclaxalapú mentőkezelés (11;14)-transzlokációs myeloma multiplexben az első vonalbeli kezelésre adott nem megfelelő válasz esetén |
|---|
| Beteiligte Personen: |
Szita, Virág Réka [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antineoplastic Agents |
|---|
| Anmerkungen: |
Date Completed 13.06.2023 Date Revised 13.06.2023 published: Electronic-Print Citation Status MEDLINE |
|---|
| doi: |
10.1556/650.2023.32790 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM358038669 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM358038669 | ||
| 003 | DE-627 | ||
| 005 | 20231226073905.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||hun c | ||
| 024 | 7 | |a 10.1556/650.2023.32790 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1193.xml |
| 035 | |a (DE-627)NLM358038669 | ||
| 035 | |a (NLM)37302128 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a hun | ||
| 100 | 1 | |a Szita, Virág Réka |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Venetoclax-based salvage in multiple myeloma with (11;14) translocation after suboptimal response to first-line therapy |
| 246 | 3 | 3 | |a Venetoclaxalapú mentőkezelés (11;14)-transzlokációs myeloma multiplexben az első vonalbeli kezelésre adott nem megfelelő válasz esetén |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 13.06.2023 | ||
| 500 | |a Date Revised 13.06.2023 | ||
| 500 | |a published: Electronic-Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a INTRODUCTION: Multiple myeloma is one of the most common hematologic malignancies, with approximately 400 patients diagnosed in Hungary annually. Novel therapies emerging in the last decade have made a great impact on most patients' survival, however, those responding poorly to standard first-line therapy and failing to proceed to stem cell transplantation face a dire prognosis. Venetoclax, a selective Bcl-2 inhibitor has been shown very effective in the treatment of relapsed/refractory t(11;14) patients, but there are only a few studies about its safety and efficacy when used as salvage in the second line | ||
| 520 | |a OBJECTIVE: The aim of our study was to analyze the data of t(11;14) patients treated with venetoclax salvage at our clinic and to evaluate its efficacy | ||
| 520 | |a METHOD: Between 2017 and 2021, 13 patients received venetoclax therapy at our clinic after suboptimal response to frontline treatment, whose data we analyzed retrospectively | ||
| 520 | |a RESULTS: Adverse prognostic markers were very prevalent in our group, 4 of our patients had del(17p), 5 had amp(1q21) and 6 had stage 3. Nevertheless, all 13 patients responded well to venetoclax therapy, with 6 reaching very good partial response and 7 complete response. All eligible patients (10) could proceed to transplantation. After median 38 months follow up, neither median progression-free, nor median overall survival was reached, since only 3 patients progressed and 1 died | ||
| 520 | |a CONCLUSION: We have shown that when salvage is needed for t(11;14) patients who respond suboptimally to standard frontline therapy, venetoclax is a remarkably good option. Orv Hetil. 2023; 164(23): 894-899 | ||
| 650 | 4 | |a English Abstract | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Bcl-2 | |
| 650 | 4 | |a multiple myeloma | |
| 650 | 4 | |a myeloma multiplex | |
| 650 | 4 | |a t(11;14) | |
| 650 | 4 | |a venetoclax | |
| 650 | 7 | |a venetoclax |2 NLM | |
| 650 | 7 | |a N54AIC43PW |2 NLM | |
| 650 | 7 | |a Antineoplastic Agents |2 NLM | |
| 650 | 7 | |a Bridged Bicyclo Compounds, Heterocyclic |2 NLM | |
| 700 | 1 | |a Wiedemann, Ádám |e verfasserin |4 aut | |
| 700 | 1 | |a Syoreni, Szabolcs |e verfasserin |4 aut | |
| 700 | 1 | |a Tóth, András |e verfasserin |4 aut | |
| 700 | 1 | |a Ruff, Eszter |e verfasserin |4 aut | |
| 700 | 1 | |a Gaál, Lilla |e verfasserin |4 aut | |
| 700 | 1 | |a Masszi, Tamás |e verfasserin |4 aut | |
| 700 | 1 | |a Varga, Gergely |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Orvosi hetilap |d 1949 |g 164(2023), 23 vom: 11. Juni, Seite 894-899 |w (DE-627)NLM000021601 |x 1788-6120 |7 nnns |
| 773 | 1 | 8 | |g volume:164 |g year:2023 |g number:23 |g day:11 |g month:06 |g pages:894-899 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1556/650.2023.32790 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 164 |j 2023 |e 23 |b 11 |c 06 |h 894-899 | ||